CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 212,051	$ 143,663
Accounts receivable	715	488
Prepaid expenses	12,292	17,434
Other current assets	307	169
Total current assets	225,365	161,754
Property, equipment, and software—net	21,791	25,154
Intangible assets—net	1,969	2,048
Right-of-use assets—net	3,289	4,180
Investment in equity securities	3,091	3,091
Equity method investment		3,751
Note receivable—net	6,711	6,879
Other assets	9,517	4,641
Total assets	271,733	211,498
Current liabilities:
Accounts payable	1,061	1,144
Accrued compensation	5,188	6,765
Accrued clinical and research and development expenses	3,285	4,028
Deferred revenue	48,405	21,244
Lease liabilities	1,981	1,822
Other current liabilities	1,228	977
Total current liabilities	61,148	35,980
Deferred revenue	90,510	67,015
Lease liabilities	3,305	4,813
Long term debt—net	22,173	2,478
Contract liabilities	10,000	10,000
Other noncurrent liabilities	217	44
Total liabilities	187,353	120,330
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.0001 par value- 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; no shares issued and outstanding as of September 30, 2022 and December 31, 2021
Common stock; $0.000005 par value- 200,000,000 shares authorized as of September 30, 2022 and December 31,2021; 111,745,219 shares issued and 110,934,747shares outstanding as of September 30, 2022; 61,712,577 shares issued and 60,902,105 shares outstanding as of December 31, 2021	1
Additional paid-in capital	485,155	408,795
Accumulated deficit	(399,824)	(316,675)
Treasury stock	(952)	(952)
Total stockholders’ equity	84,380	91,168
Total liabilities and stockholders’ equity	$ 271,733	$ 211,498